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Abstract
Background: Few treatment options for alcohol use disorders (AUDs) exist and more are critically needed. Here, we assessed 
whether trace amine associated receptor 1 (TAAR1), a modulator of brain monoamine systems, is involved in the behavioral and 
  reinforcement-related effects of ethanol and whether it could potentially serve as a therapeutic target.
Methods: Wild-type (WT) and TAAR1 knockout (KO) mice (75% C57J/BL6 and 25% 129S1/Sv background) were compared in tests 
of ethanol consumption (two-bottle choice [TBC]), motor impairment (loss of righting reflex, [LORR], locomotor activity) and ethanol 
clearance (blood ethanol level [BEL]).
Results: As compared with WT mice, KO mice displayed (1) significantly greater preference for and consumption of ethanol in a 
TBC paradigm (3%–11% vol/vol escalating over 10 weeks), with no significant difference observed in TBC with sucrose (1%–3%); 
(2) significantly greater sedative-like effects of acute ethanol (2.0 or 2.5 g/kg, intraperitoneal [i.p.]) manifested as LORR observed at 
a lower dose and for longer time, with similar BELs and rates of ethanol clearance; and (3) lower cumulative locomotor activity over 
60 minutes in response to an acute ethanol challenge (1.0–2.5 g/kg, i.p.).
Conclusions: The present findings are the first to implicate TAAR1 in the behavioral and reinforcement-related effects of ethanol and 
raise the question of whether specific drugs that target TAAR1 could potentially reduce alcohol consumption in humans with AUDs.
Keywords: alcoholism, treatment, reward, addiction, dopamineLynch et al
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Introduction
Along  with  cognitive,  behavioral,  and  spiritual 
approaches, medications are used to assist in reduc-
ing alcohol consumption or craving during abstinence. 
Three medications are approved in the United States for 
treating alcoholism. These are: (1) disulfiram, an acet-
aldehyde dehydrogenase blocker that causes an adverse 
reaction to alcohol due to accumulation of acetalde-
hyde; (2) naltrexone, a substituted oxymorphone that 
functions as an opioid receptor antagonist. Naltrexone 
reduces the desire for alcohol and helps some motivated 
problem drinkers stay sober; and (3) acamprosate, a 
drug that alters excitatory activity of NMDA receptors. 
Acamprosate reduces the physical distress and emo-
tional discomfort of craving. Each of these drugs have 
variable effectiveness and acceptance levels within pop-
ulations and are used by a minority of people harboring 
a medical diagnosis of alcoholism. Additionally, cur-
rently available medications are prescribed to individu-
als who have already stopped drinking and are trying to 
maintain alcohol abstinence. There are no medications 
that are prescribed for people who are actively drinking 
alcohol yet want to stop drinking. Accordingly, more 
and better treatment options for alcoholism and preven-
tion of AUDs is a major objective.
Trace amine associated receptor 1 (TAAR1) is a G 
protein–coupled receptor that is expressed in monoam-
inergic brain regions implicated in the reward pathway, 
including the nucleus accumbens, ventral tegmental 
area, and substantia nigra.1–3 TAAR1 is activated by a 
wide spectrum of endogenous ligands including clas-
sic biogenic amines, trace amines, and thyronamines 
and is also a direct target of psychostimulant drugs of 
abuse including amphetamine, methamphetamine, and 
3,4-methylenedioxy-N-methamphetamine.3–5 Receptor 
activation results in cAMP/PKA and Ca++/PKC sig-
naling  and  phosphorylation  of  PKA  and  PKC.1,4,6,7 
In  monoaminergic  synaptosomes,  cellular  signaling 
pathways elicited from TAAR1 activation modulate 
dopamine  transporter  (DAT),  norepinephrine  trans-
porter (NET), and serotonin transporter (SERT) kinetic 
activity (inhibit uptake and promote efflux) as well as 
DAT internalization.7–10 In brain slices of the ventral 
tegmental area and dorsal raphe nucleus, TAAR1 acti-
vation inhibits the firing frequency of dopaminergic 
and serotonergic neurons, respectively.11,12
Given the ability of TAAR1 to modulate dopamine 
as well as other monoamines8,13 and the   involvement 
of dopamine as well as other monoamines in   alcohol 
abuse,14,15 this study tested the hypothesis that TAAR1 
is involved in the behavioral and reinforcement-related 
effects of ethanol. The effects of ethanol in wild-type 
(WT, 75% C57J/BL6 and 25% 129S1/Sv) and con-
genic TAAR1 knockout (KO) mice were compared in 
tests of ethanol consumption (2-bottle choice [TBC]), 
motor impairment (loss of righting reflex [LORR]), 
locomotor activity and the ethanol clearance (blood 
ethanol levels [BEL]). The findings provide the first 
evidence that the TAAR1 receptor is a modulator of 
ethanol responsiveness and ethanol-related behaviors 
and suggest that TAAR1-targeted drugs be investi-
gated as potential therapeutics for combating AUDs.
Materials and Methods
Subjects
Homozygous  male  and  female  WT  (+/+)  and  KO 
(-/-)  mice  (strain  background:  75%  C57BL/6J  and 
25% 129S1/Sv) were maintained on a 12-hour light/
dark  lighting  schedule  at  a  room  temperature  of 
22 °C ± 1 °C with food and water available ad libitum. 
All  experiments  were  conducted  during  the  middle 
hours of the light cycle. The KO mice were derived 
from  heterozygous  breeding  pairs,  originally  gifted 
from  Lundbeck  Research  USA,  Inc  (Paramus,  NJ). 
Their  origination  has  been  previously  described.16 
Briefly,  KO  mice  lack  the  coding  sequence  of  the 
TAAR1 gene (which is a single exon) as well as 1.0 
kilobase (kb) of upstream sequence and 1.3 kb of down-
stream sequence. The deleted sequence was replaced 
with a neo cassette in reverse orientation. Accordingly, 
the KO mice do not express TAAR1 protein. Mice 
were generally 8 to 12 weeks old at the time of study, 
with the exception of LORR and BEL measurements 
that used some mice that were 24 weeks old at the time 
of study. Due to funding limitations, we used available 
populations of mice for the different behavioral testing 
paradigms, which were performed sequentially over 
time. In this regard, we controlled for age and sex 
within each behavioral test to the best of our abilities. 
All animal care was in accordance with the Guide for 
the  Care and Use  of  Laboratory Animals  (National 
Research Council, National Academy Press, 1996) and 
all procedures were conducted in accordance with the 
  Animal  Experimentation  Protocol  #04184  approved 
by the Harvard Medical Area Standing Committee on 
Animals.TAAR1 modulation of ethanol behaviors
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Solutions
For  2-bottle  choice,  200-proof  ethanol  (Pharmco-
AAPER, Brookfield, CT) was diluted into tap water 
at concentrations ranging from 3% to11% (vol/vol). 
Sugar (Office Snax, Hinsdale, IL) was dissolved into 
tap water at concentrations of either 1% or 3% (wt/
vol), and 200-proof ethanol was diluted into saline at 
20% vol/vol for i.p. injections.
equipment
For 2-bottle choice, large breeding cages (10 × 18 in) 
were equipped with tops that were custom modified 
to allow access to two 50 mL drinking tubes equipped 
with Lixit valves (Med Associates Inc., St. Albans, 
VT).  For  LORR  assessments,  a  custom-designed 
trough was made of metal shaped in an upside down 
W with a sheet of Plexiglas covering it. Locomotor 
assessments  were  conducted  in  ventilated,  sound-
attenuated  chambers  with  white  background  noise 
(MED Associates, St. Albans, VT). The square open-
field plexiglas arena (11 cm × 11 cm) within each 
chamber was equipped with 3 rows of infrared light-
sensitive photocells mounted at 40, 115, and 195 mm 
above  the  floor.  All  locomotor  assessments  were 
performed under illuminated conditions. An Analox 
AM1 series analyzer (Analox Instruments USA Inc., 
Lunenburg, MA) was used to determine BELs. Each 
apparatus was sanitized between animals.
The 2-bottle choice: ethanol versus 
water
The 2-bottle choice procedures allow for measurement 
of ethanol preference and intake under conditions of 
voluntary consumption. In our studies, a counterbal-
anced procedure was employed. Naïve female mice 
(approximately 20–24 g) were pair housed and were 
8 to 12 weeks old at study initiation (n = 9 cages per 
genotype). Mice were allowed to drink from either 
a drinking tube filled with tap water or a drinking 
tube filled with escalating concentrations (3%, 5%, 
7%, 9%, and 11% vol/vol) of ethanol. Drinking tubes 
were set up Monday and made continuously avail-
able through Friday. Tubes were weighed Monday, 
Wednesday,  and  Friday  to  determine  the  weight 
of each liquid consumed. Fluids in the tubes were 
refreshed and tube positions oscillated on Wednes-
days to control for side biases. The mice remained 
at each concentration of ethanol for 2 5-day testing 
sessions, with a single water bottle that was oscillated 
each weekend (for a total of 2 weeks), after which 
they would advance to the next highest concentration 
of ethanol. For each 2-week period, an average num-
ber of grams per day per cage was obtained for both 
the ethanol bottle and the water bottle, and the per-
cent drinking from the ethanol bottle relative to the 
total amount of liquid consumed was calculated.
Two-bottle choice: sucrose solution 
versus water
To determine the generality of any effects observed 
with ethanol, preference for a nonethanol caloric bev-
erage  was  also  assessed. Age-matched,  naïve,  and 
paired female mice were assessed in parallel using 
the same paradigm as above with escalating concen-
trations (1% and 3% w/v) of sucrose solution versus 
water (n = 4 cages per genotype).
Loss of righting reflex (LORR)
Duration of LORR is typically thought to measure the 
anesthetic or sedative actions of ethanol. Here, naïve 
male  and  female  WT  and  KO  mice  (2.5–6  months 
of  age)  were  injected  with  ethanol.  Three  doses  of 
ethanol were tested: (1) 18 (6 male and 3 female WT 
and KO) mice were assessed following 1.5 g/kg, i.p.; 
(2) 22 (7 female and 4 male WT, 5 female and 6 male KO) 
mice were assessed following 2.0 g/kg, i.p.; and (3) 38 
(7 female and 12 male WT and KO) mice were assessed 
following 2.5 g/kg, i.p. Each mouse was placed into a 
clean holding cage for 1 minute. Mice were then placed 
in the supine position in a V-shaped trough 2 times con-
secutively every minute to assess ability to right. LORR 
was defined as the time interval spanning from the ini-
tiation of an inability to right for at least 1 full minute 
until the mouse could right 2 times consecutively. If no 
LORR was observed, the test concluded at 20 minutes.
Locomotor activity
Locomotor activity in naïve male and female WT and 
KO mice (11–13 weeks old) was assessed following 
i.p. administration of saline, 1.0, 1.5, 2.0, or 2.5 g/kg 
ethanol (n = 4 per genotype, per dose, and per sex). 
Following a 20 minute habituation to the test cham-
ber apparatus, mice were assessed for a 1-hour period. 
Additionally,  a  group  of  older  WT  and  KO  mice 
(9 months old, n = 8 per genotype) that had 2 previous 
exposures to ethanol were also assessed   following a Lynch et al
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2.0 g/kg, i.p. dose and 15 minutes of habituation, for 
a 2-hour period (Supplemental Fig. 1).
Determination of BeLs
We assessed BEL in male and female WT and KO 
mice  (approximately  50–50  split,  as  indicated; 
2–8  months  old)  treated  with  2.5  g/kg  ethanol 
(i.p.). At selected time points (2, 5, 10, 20, 30, 45, 
180 minutes, 19 hours and 24 hours), animals were 
euthanized and trunk blood was collected for deter-
mination of BELs. Blood samples were immediately 
centrifuged at 3200 rpm for 8 to 12 minutes. The 
plasma was drawn off, transferred to polypropylene 
tubes, and then frozen until analysis. Triple determi-
nations of BALs were conducted using a rapid high 
performance plasma alcohol analysis using alcohol 
oxidase with an AM1 series analyzer and Analox Kit 
GMRD-113 (Analox Instruments USA, Lunenberg, 
MA).17 This process detects BEL ranges from 0 to 
350 mg/dL using an internal standard of 100 mg/dL.
Results
Two-bottle choice
We assessed whether WT and KO mice differed in 
their  preference  for  drinking  ethanol  using  a  two-
bottle  choice  paradigm. WT  and  KO  mice  differed 
in  the  percent  of  total  drinking  that  was  from  the 
ethanol bottle (Fig. 1A). Overall, KO mice drank a 
  significantly greater volume of ethanol solution versus 
water  as  compared  with  WT  mice  (2-way  analy-
sis of variance [ANOVA], F1,16 = 23.59, P , 0.001). 
Genotype accounted for 19.85% of the total variance 
in bottle choice. The magnitude of this difference was 
dependent on ethanol concentration, which also had 
overall  significance  (2-way ANOVA,  F4,64  =  19.09, 
P , 0.001, Bonferroni t tests, P , 0.001 at the 5% 
ethanol concentration; P , 0.05 at 3% and 7% ethanol 
concentrations), which accounted for 34.38% of the 
variance. This choice behavior resulted in the KO mice 
consuming more total ethanol per day (on average) 
than WT mice at every concentration tested (Table 1).
We also analyzed the total amount of liquid con-
sumed by the WT and KO mice during each 2-week 
interval as the concentration of ethanol solution avail-
able increased. WT and KO mice differed in the amount 
(grams) of total liquid (ethanol plus water) that they 
consumed (Fig. 1B). Overall, WT mice consistently 
drank more total liquid than KO mice (2-way ANOVA, 
F1,16  =  6.32,  P  =  0.023),  with  genotype  accounting 
for 15.8% of the total variance. The concentration of 
ethanol solution available was also an overall signifi-
cant factor (2-way ANOVA, F4,64 = 5.12, P = 0.0012, 
  Bonferroni t tests, P , 0.01 at the 5% ethanol concen-
tration), accounting for 9.66% of the total variance.
In contrast to ethanol two-bottle choice, WT and 
KO mice showed no significant difference in the per-
cent of total drinking that was from the sucrose bottle 
in a sucrose two-bottle choice experiment, at either 
1% or 3% concentrations of sucrose (Fig. 1C).
Loss of righting reflex (LORR)
No  mice  showed  LORR  following  1.5  g/kg  etha-
nol (n = 9 per genotype, Fig. 2A). At 2.0 g/kg, 5 of 
11 KO mice showed LORR that lasted between 25 to 
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110 minutes, whereas none of the 11 WT mice dis-
played  LORR  (n  =  11  per  genotype,  Fig.  2B). At 
2.5 g/kg, all mice all displayed LORR, and LORR 
in KO mice continued as much as 40 minutes longer 
than any WT tested (n = 19 per genotype, Fig. 2C).
Locomotion
Naïve male and female WT and KO mice were admin-
istered  saline  or  a  1.0 g/kg,  1.5 g/kg,  2.0 g/kg,  or 
2.5 g/kg i.p. injection of ethanol (20% vol/vol), and 
locomotor activity was measured for 60 minutes in 
an activity chamber at 5-minute intervals. There were 
no  overall  significant  differences  between  KO  and 
WT mice of either sex at any of the doses of ethanol 
tested, but there was a significant difference between 
measures at different time points (2-way ANOVA per-
formed on each line graph in Fig. 3: genotype, ns; time 
points, F12,72 = 2.77 to 12.60, P , 0.01 in each analysis, 
Bonferroni t tests as indicated in Fig. 3 line graphs). 
Cumulative counts over the 60-minute test interval 
were also analyzed (Fig. 3, bar graphs). Female KO 
mice showed   significantly lower levels of total loco-
motion over the 60-minute test period following expo-
sure to 2.5 g/kg ethanol (t test, P , 0.01, Fig. 3E), as 
did male KO mice following exposure to 1.0 g/kg eth-
anol (t test, P , 0.01, Fig. 3B). Also, when male and 
female data were combined and analyzed, KO mice 
showed significantly lower levels of total locomotion 
over the 60-minute test period following exposure to 
2.5 g/kg ethanol (t test, P , 0.01, Fig. 3E). Lastly, an 
additional group of WT and KO mice (n = 6 male and 
2 female for each genotype) which had been exposed 
for the first time to ethanol on each of the 2 previous 
days was tested on the third day with a 2.0 g/kg dose 
of ethanol (i.p.) and locomotor activity was measured 
for 120 minutes in an activity chamber at 5-minute 
intervals  (Supplemental  Fig.  1).  Overall,  a  similar 
pattern was observed, with KO mice showing signifi-
cantly lower locomotor activity as compared with WT 
mice (2-way ANOVA, genotype and time: genotype, 
F1,14 = 5.85, P , 0.03; time, F24,336 = 11.73, P , 0.001; 
Bonferroni t tests, as indicated, P , 0.01).
Blood ethanol level (BeL)
To investigate whether WT and KO mice differ in 
their ability to metabolize ethanol, BELs were mea-
sured following injection of 2.5 g/kg ethanol (i.p.) in 
separate groups of WT and KO mice and then eutha-
nized at different time points (0.03–24 hours postin-
jection; number and sex of mice are matched between 
genotypes and are indicated in Fig. 4, top). Data were 
analyzed  using  noncompartmental  pharmacokinetic 
analysis (PKSolver, see Zhang et al).18 All pharma-
cokinetic parameters between genotypes were almost 
Table 1. Average ethanol consumed per day during each 
2-week  period  of  ascending  concentrations  of  ethanol 
availability.
% ethanol Genotype g/kg/day/mouse
3% WT 3.04 ± 0.73
KO 4.85 ± 0.47
5% WT 6.35 ± 1.21
KO 10.13 ± 0.87
7% WT 7.96 ± 1.65
KO 12.03 ± 1.49
9% WT 5.74 ± 1.08
KO 9.56 ± 1.78
11% WT 3.2 ± 1.19
KO 5.32 ± 1.54
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identical (see Fig. 4, bottom), including elimination 
half-life  (t1/2),  maximal  concentration  (Cmax),  area 
under the curve from 0 to last time (AUC0-t), clear-
ance rate (Cl), volume of distribution based on termi-
nal slope (Vz) and mean residence time (MRT).
Discussion
The  present  study  demonstrates  that  deletion  of 
TAAR1 in mixed-strain (background 75% C57BL/6J 
and 25% 129S1/Sv) mice results in adult KO mice 
that  show  a  greater  preference  for  ethanol  and 
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Figure 3. Locomotion. Male and female WT (solid lines and bars) and KO (dotted lines and striped bars) were administered saline (A), 1.0 g/kg (B), 
1.5 g/kg (c), 2.0 g/kg (D) or 2.5 g/kg (e) ethanol (20% vol/vol) by i.p. injection, and locomotor activity was measured in 5-minute intervals for 60 minutes 
(n = 4 per genotype per dose). There were no overall significant differences between KO and WT mice of either sex at any of the doses of ethanol tested, 
but there was an overall significant difference between measures at different time points (2-way ANOVA, F12,72 = 2.77 to 12.60, P , 0.01 in each analysis, 
Bonferroni t tests *P , 0.05, **P , 0.01). Female KO mice showed significantly lower levels of total locomotion over the 60-minute test period following 
exposure to 2.5 g/kg ethanol (t test, **P , 0.01, row E), as did male KO mice following exposure to 1.0 g/kg ethanol (t test, **P , 0.01, row B). With both 
sexes combined, KO mice showed significantly lower levels of total locomotion over the 60-minute test period following exposure to 2.5 g/kg ethanol (t test, 
**P , 0.01, row e).TAAR1 modulation of ethanol behaviors
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  consume more ethanol than their WT counterparts. 
The  TAAR1  KO  mice  in  this  study  also  had  a 
greater sensitivity to the sedative effects of ethanol 
and showed a longer duration of motor impairment 
following ethanol exposure, yet KO and WT mice 
showed similar ethanol pharmacokinetics. Consistent 
with this observation, a greater reduction in locomo-
tion in response to ethanol was also observed in the 
KO mice as compared with WT mice. These findings 
are the first to implicate a role for TAAR1 in the 
behavioral and reinforcement-related effects of etha-
nol and raise the question of whether specific drugs 
that target TAAR1 could potentially reduce alcohol 
consumption in humans with AUDs.
In the absence of any overt behavioral abnormali-
ties under baseline conditions, KO mice show a phar-
macogenic  phenotype  of  an  enhanced  locomotive 
response  to  amphetamine  and  methamphetamine, 
coincident with an increase in the release of biogenic 
amines.2,16,19 Consistent with the augmented locomotor 
response, KO mice acquire   methamphetamine-induced 
conditioned  place  preference  (CPP)  earlier  than 
WT  mice  and  retain  CPP  longer  during  extinction 
training.19  Notably  though,  both  genotypes  display 
similar levels of morphine-induced CPP. These data 
suggest that TAAR1 plays a modulatory role in the 
behavioral  sensitization  to  amphetamine-based 
psychostimulants and a selective role in the condi-
tioned reinforcing effects of methamphetamine versus 
morphine. This differential effect may involve dop-
amine in that dopamine released by amphetamine (or 
methamphetamine) interacts with dopamine D1 (and 
D2) receptors to establish CPP,20 whereas D1 recep-
tors are reportedly not required for morphine-induced 
CPP.21 In this regard, other drugs of abuse also involve 
dopamine  receptor-dependent  reward  mechanisms, 
including ethanol. Both dopamine D1 and D2 receptor 
mechanisms have been implicated in ethanol-seeking 
behavior in mice.22 Dopamine D3 receptors are also 
implicated in ethanol seeking and relapse behaviors 
in mice and rats23–25 as well as in ethanol preference 
and intake in alcohol-preferring in rats.26 Collectively, 
and in the context of the present study, the pharma-
cogenic phenotypes observed in KO mice along with 
the ability of TAAR1 activation to regulate dopamine 
suggest  that  TAAR1  is  a  modulator  of  dopamine-
mediated rewarding effects of drugs of abuse. Nota-
bly, this includes amphetamine-like psychostimulants 
such  as  methamphetamine,  which  directly  binds  to 
the receptor, as well as ethanol, which may indirectly 
alter TAAR1 signaling via its ability to affect levels of 
endogenous TAAR1 agonists (eg, dopamine, but also 
trace amines). Additionally, TAAR1-mediated effects 
on NET and SERT function suggest a pharmacology 
for the TAAR1 receptor that is unique and distinct 
from other monoamine receptors. In this regard, the 
present study warrants further investigation of TAAR1 
as a potential therapeutic target for addictive disor-
ders  generally  and  for AUDs  specifically  that  may 
function in a distinctly different manner than current 
pharmacotherapies.9,10,13,27
TAAR1  was  discovered  in  2001,1,4  but  specific 
drugs that target the receptor did not come along until 
recently.11,28–32 The discovery of compounds that spe-
cifically target TAAR1 is now enabling deeper inves-
tigations into the role of TAAR1 in the rewarding 
effects of drugs of abuse. For example, Revel et al29 
showed that the TAAR1 agonist RO5166017 inhib-
ited the firing frequency of dopamine and serotonin 
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Figure 4. Blood ethanol level (BEL). We assessed BELs in KO and WT 
mice (n = 4–11 mice per time point, as indicated) that were administered 
a 2.5 g/kg dose of ethanol (i.p.). Pharmacokinetic analysis showed no dif-
ferences between genotype for any relevant parameter associated with 
ethanol metabolism.Lynch et al
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neurons in regions where TAAR1 is expressed (eg, 
VTA  and  dorsal  raphe  nucleus)  and  blocked  dop-
amine-dependent hyperlocomotion in cocaine-treated 
mice and DAT knockout mice as well as hyperactivity 
induced by an NMDA antagonist. Mice injected with 
cocaine  displayed  elevated  locomotor  activity,  and 
RO5166017 given orally prevented this effect in a 
dose-dependent manner. RO5166017 alone had little 
or no effect on locomotion. In KO mice, cocaine ele-
vated locomotor activity to a similar extent as in WT 
mice, but only in WT mice did RO5166017 prevent 
the cocaine-induced hyperlocomotion. Interestingly, 
RO5166017 also inhibited stereotypies induced by 
cocaine in WT mice, and this effect was lost in the 
KO mice. Lastly, the first potent and selective TAAR1 
partial  agonist,  RO5203648,  specifically  blocked 
cocaine self administration in rats.30 The drug did not 
significantly alter operant responding for 10% sucrose 
or increases in the reinforcing effectiveness of sucrose 
under a progressive ratio schedule of reinforcement, 
suggesting  that  a  TAAR1  partial  agonist  does  not 
impair motor or motivational processes. Accordingly, 
compounds that target TAAR1 are capable of modify-
ing self administration of cocaine, and accordingly, in 
the context of the present data implicating a role for 
TAAR1 in modulating ethanol-induced behaviors, it 
is reasonable to speculate that these compounds may 
be efficacious in altering self administration of etha-
nol as well.
It is notable that TAAR1 mRNA and protein have 
been detected in a variety of brain areas including 
many of the areas that are critical to the “alcohol” 
circuitry, such as the nucleus accumbens, amygdala, 
hippocampus,  substantia  nigra,  ventral  tegmental 
area, and raphe nuclei.1–3,10 While this receptor has 
been studied extensively in the monoamine system, 
it is largely unstudied in other brain regions. TAAR1 
agonist  treatment  of  striatal  or  thalamic  synapto-
somes  promotes  changes  in  DAT/SERT  and  NET 
kinetic activity, respectively, by promoting PKA and 
PKC phosphorylation cascades,9,10 so it is likely that 
TAAR1  expressed  in  other  brain  regions  can  also 
promote  PKA  and  PKC  signaling  cascades  upon 
stimulation.
In summary, this is the first study to investigate the 
involvement of TAAR1 in the biological and behav-
ioral  effects  of  ethanol.  The  enhanced  preference, 
  consumption, and sedative effects of ethanol observed 
in KO mice demonstrate a role for TAAR1 in modulat-
ing the behavioral and reinforcement-related effects of 
ethanol. These findings suggest that TAAR1 may be 
part of a novel mechanism contributing to the effects 
of ethanol in the brain and that TAAR1-targeted com-
pounds may have potential as candidate medications 
for AUDs. Defining a role for TAAR1 in modulating 
the effects of ethanol can have a large potential impact. 
If efficacious, TAAR1-targeted drugs would function 
through a mechanism distinct from other clinically 
available drugs used for treating alcoholism/AUDs or 
those that are in preclinical or clinical trials. Further, 
they may have fewer side effects, in that they may 
regulate brain monoamines without binding directly 
to monoamine transporters and/or classic monoamine 
receptors.8,13,27
Acknowledgements
We  thank  the  NEPRC  Primate  Genetics  Core  for 
mouse genotyping services.
Author contributions
Conceived  and  designed  the  experiments:  GMM, 
LJL,  KAS,  EJV,  DMP. Analyzed  the  data:  GMM, 
LJL, EJV, JKR, DMP. Wrote the first draft of the 
manuscript: GMM, LJL. Contributed to the writing 
of the manuscript: GMM, LJL, DMP, JKR. Agree 
with manuscript results and conclusions: GMM, LJL, 
KAS, EJV, JKR, DMP. Jointly developed the struc-
ture and arguments for the paper: GMM, LJL, DMP. 
Made critical revisions and approved final version: 
GMM, DMP. All authors reviewed and approved of 
the final manuscript.
Funding
This  research  was  supported  by  grants  from  NIH: 
K02DA025697 (GMM) and OD011103 (NEPRC).
competing Interests
Author(s) disclose no potential conflicts of interest.
Disclosures and ethics
As  a  requirement  of  publication  the  authors  have 
  provided signed confirmation of their compliance with 
ethical and legal obligations including but not lim-
ited to compliance with ICMJE authorship and com-
peting interests guidelines, that the article is neither 
under  consideration  for  publication  nor  published TAAR1 modulation of ethanol behaviors
Substance Abuse: Research and Treatment 2013:7  125
elsewhere, of their compliance with legal and ethi-
cal guidelines concerning human and animal research 
participants (if applicable), and that permission has 
been obtained for reproduction of any copyrighted 
material. This article was subject to blind, indepen-
dent, expert peer review. The reviewers reported no 
competing interests.
References
  1.  Borowsky B, Adham N, Jones KA, et al. Trace amines: identification of 
a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci 
U S A. 2001;98(16):8966–71.
  2.  Lindemann  L,  Meyer  CA,  Jeanneau  K,  et  al.  Trace  amine-associated 
receptor  1  modulates  dopaminergic  activity.  J  Pharmacol  Exp  Ther. 
2008;324(3):948–56.
  3.  Xie Z, Westmoreland SV, Bahn ME, et al. Rhesus monkey trace amine-
associated receptor 1 signaling: enhancement by monoamine transporters 
and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 
2007;321(1):116–27.
  4.  Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-  meth
ylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites 
of the catecholamine neurotransmitters are agonists of a rat trace amine 
  receptor. Mol Pharmacol. 2001;60(6):1181–8.
  5.  Scanlan TS, Suchland KL, Hart ME, et al. 3-Iodothyronamine is an endoge-
nous and rapid-acting derivative of thyroid hormone. Nat Med. 2004;10(6): 
638–42.
  6.  Panas  MW,  Xie  Z,  Panas  HN,  Hoener  MC,  Vallender  EJ,  Miller  GM. 
Trace Amine Associated Receptor 1 Signaling in Activated Lymphocytes. 
J   Neuroimmune Pharmacol. 2012;7(4):866–76.
  7.  Xie Z, Miller GM. A receptor mechanism for methamphetamine action in 
dopamine transporter regulation in brain. J Pharmacol Exp Ther. 2009; 
330(1):316–25.
  8.  Miller GM. The emerging role of trace amine-associated receptor 1 in the 
functional regulation of monoamine transporters and dopaminergic activity. 
J Neurochem. 2011;116(2):164–76.
  9.  Xie Z, Miller GM. Beta-phenylethylamine alters monoamine transporter 
function via trace amine-associated receptor 1: implication for modulatory 
roles of trace amines in brain. J Pharmacol Exp Ther. 2008;325(2):617–28.
  10.  Xie Z, Westmoreland SV, Miller GM. Modulation of monoamine transport-
ers by common biogenic amines via trace amine-associated receptor 1 and 
monoamine autoreceptors in human embryonic kidney 293 cells and brain 
synaptosomes. J Pharmacol Exp Ther. 2008;325(2):629–40.
  11.  Bradaia A, Trube G, Stalder H, et al. The selective antagonist EPPTB reveals 
TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the 
mesolimbic system. Proc Natl Acad Sci U S A. 2009;106(47):20081–6.
  12.  Rao A, Simmons D, Sorkin A. Differential subcellular distribution of endo-
somal compartments and the dopamine transporter in dopaminergic   neurons. 
Mol Cell Neurosci. 2011;46(1):148–58.
  13.  Miller GM. Avenues for the development of therapeutics that target trace 
amine associated receptor 1 (TAAR1). J Med Chem. 2012;55(5):1809–14.
  14.  Kash TL. The role of biogenic amine signaling in the bed nucleus of the stria 
terminals in alcohol abuse. Alcohol. 2012;46(4):303–8.
  15.  Soderpalm B, Ericson M. Neurocircuitry involved in the development of 
alcohol addiction: the dopamine system and its access points. Curr Top 
Behav Neurosci. 2013;13:127–61.
  16.  Wolinsky TD, Swanson CJ, Smith KE, et al. The Trace Amine 1 receptor 
knockout mouse: an animal model with relevance to schizophrenia. Genes 
Brain Behav. 2007;6(7):628–39.
  17.  Vallender EJ, Ruedi-Bettschen D, Miller GM, Platt DM. A pharmacogenetic 
model of naltrexone-induced attenuation of alcohol consumption in rhesus 
monkeys. Drug Alcohol Depend. 2010;109(1–3):252–6.
  18.  Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharma-
cokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput 
Methods Programs Biomed. 2010;99(3):306–14.
  19.  Achat-Mendes  C,  Lynch  LJ,  Sullivan  KA,  Vallender  EJ,  Miller  GM. 
  Augmentation of methamphetamine-induced behaviors in transgenic mice 
lacking the trace amine-associated receptor 1. Pharmacol Biochem Behav. 
2012;101(2):201–7.
  20.  Hiroi  N,  White  NM.  The  amphetamine  conditioned  place    preference: 
  differential  involvement  of  dopamine  receptor  subtypes  and  two 
  dopaminergic terminal areas. Brain Res. 1991;552(1):141–52.
  21.  Urs  NM,  Daigle  TL,  Caron  MG.  A  dopamine  D1  receptor-dependent 
  beta-arrestin  signaling  complex  potentially  regulates  morphine-induced 
psychomotor activation but not reward in mice.   Neuropsychopharmacology. 
2011;36(3):551–8.
  22.  El-Ghundi M, George SR, Drago J, et al. Disruption of dopamine D1 recep-
tor gene expression attenuates alcohol-seeking behavior. Eur J Pharmacol. 
1998;353(2–3):149–58.
  23.  Heidbreder  CA, Andreoli  M,  Marcon  C,  Hutcheson  DM,  Gardner  EL, 
Ashby CR Jr. Evidence for the role of dopamine D3 receptors in oral operant 
alcohol self-administration and reinstatement of alcohol-seeking   behavior 
in mice. Addict Biol. 2007;12(1):35–50.
  24.  Vengeliene V, Leonardi-Essmann F, Perreau-Lenz S, et al. The dopamine 
D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J. 
2006;20(13):2223–33.
  25.  Rice OV, Patrick J, Schonhar CD, Ning H, Ashby CR Jr. The effects of the 
preferential dopamine D(3) receptor antagonist S33138 on ethanol binge 
drinking in C57BL/6J mice. Synapse. 2012;66(11):975–8.
  26.  Thanos PK, Katana JM, Ashby CR Jr, et al. The selective dopamine D3 
receptor antagonist SB-277011-A attenuates ethanol consumption in etha-
nol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav. 
2005;81(1):190–7.
  27.  Xie Z, Miller GM. Trace amine-associated receptor 1 as a monoaminergic 
modulator in brain. Biochem Pharmacol. 2009;78(9):1095–104.
  28.  Revel FG, Meyer CA, Bradaia A, et al. Brain-specific overexpression of 
trace amine-associated receptor 1 alters monoaminergic neurotransmission 
and  decreases  sensitivity  to  amphetamine.  Neuropsychopharmacology. 
2012;37(12):2580–92.
  29.  Revel FG, Moreau JL, Gainetdinov RR, et al. TAAR1 activation modulates 
monoaminergic neurotransmission, preventing hyperdopaminergic and hypo-
glutamatergic activity. Proc Natl Acad Sci U S A. 2011;108(20):8485–90.
  30.  Revel  FG,  Moreau  JL,  Gainetdinov  RR,  et  al.  Trace  amine-associated 
  receptor  1  partial  agonism  reveals  novel  paradigm  for  neuropsychiatric 
therapeutics. Biol Psychiatry. 2012;72(11):934–42.
  31.  Revel FG, Moreau JL, Pouzet B, et al. A new perspective for   schizophrenia: 
TAAR1  agonists  reveal  antipsychotic-  and  antidepressant-like  activity, 
improve cognition and control body weight. Mol Psychiatry. 2013;18(5): 
543–56.
  32.  Hart ME, Suchland KL, Miyakawa M, Bunzow JR, Grandy DK, Scanlan TS. 
Trace  amine-associated  receptor  agonists:  synthesis  and  evaluation  of 
  thyronamines and related analogues. J Med Chem. 2006;49(3):1101–12.Lynch et al
126  Substance Abuse: Research and Treatment 2013:7
Figure s1. Locomotion. An   additional group of WT and KO mice (n = 6 male and 2 female for each genotype) which had been exposed for the first time 
to ethanol on each of 2 days prior days was tested on the third day with a 2.0 g/kg dose of ethanol and locomotor activity was measured for 120   minutes 
in an activity chamber at 5-minute   intervals. KO mice showed significantly lower locomotor activity as compared with WT mice (2-way ANOVA, genotype 
and time: genotype, F1,14 = 5.85, P , 0.03; time, F24,336 = 11.73, P , 0.001; Bonferroni t tests **P , 0.01).
supplemental Figure